Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144455 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by ImmunoGenesis.
- Completed
- Registry status
- Phase 2
- Development phase
- 214
- Enrollment target
NCT01144455 is a Phase 2 study that has completed, run by ImmunoGenesis. The registered enrollment target is 214 participants.
The verdict
NCT01144455, a Phase 2 study, has completed, sponsored by ImmunoGenesis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 214 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Gemcitabine versus Gemcitabine and TH-302 are effective in the treatment of subjects with first-line metastatic pancreatic adenocarcinoma.
Interventions
- DRUG TH-302
- DRUG Gemzar (Gemcitabine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144455
The ClinicalTrials.gov registry entry for NCT01144455 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGenesis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TH-302 is the first listed.
NCT01144455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01144455 about?
NCT01144455 is a clinical study titled "Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma". The purpose of this study is to determine whether Gemcitabine versus Gemcitabine and TH-302 are effective in the treatment of subjects with first-line metastatic pancreatic adenocarcinoma.
What is the current status of trial NCT01144455?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2010-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01144455?
The interventions under investigation include: TH-302 (DRUG), Gemzar (Gemcitabine) (DRUG).
Who is sponsoring clinical trial NCT01144455?
This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.